Search results
Oct 3, 2016 · The affinity ligand can consist of a wide variety of binding agents, ranging from a protein or enzyme to an antibody, an antigen, a sequence of DNA or RNA, a biomimetic dye, an enzyme substrate or inhibitor, or a low mass compound (e.g., a drug or hormone). The affinity ligand is immobilized within a column and used to selectively bind a given ...
- PMC Free Article
INTRODUCTION. Griffithsin (GRFT) is a lectin isolated from...
- Detection of Heterogeneous Drug-Protein Binding by Frontal Analysis and High-Performance Affinity Chromatography
In these equations, m Lapp is the apparent moles of analyte...
- A Robust Method to Evaluate Receptor–Ligand Interactions
The binding of Gal is regarded as the ‘anchor’ of the...
- Analysis of Drug Interactions With High Density Lipoprotein by High-Performance Affinity Chromatography
Two drugs known to bind with HDL are propranolol and...
- Binding of Tolbutamide to Glycated Human Serum Albumin
2.1 Frontal Analysis. Frontal analysis (or frontal affinity...
- Measurement of Drug-Protein Dissociation Rates by High-Performance Affinity Chromatography and Peak Profiling
The rate at which a drug or other small solute interacts...
- Chromatographic Analysis of Acetohexamide Binding to Glycated Human Serum Albumin
1. Introduction. Human serum albumin (HSA) is the most...
- Analysis of Lidocaine Interactions With Serum Proteins Using High-Performance Affinity Chromatography
High-performance affinity chromatography was used to study...
- Evaluation of Affinity Microcolumns Containing Human Serum Albumin for Rapid Analysis of Drug-Protein Binding
1. Introduction. Interactions between drugs and serum...
- PMC Free Article
Jul 1, 2022 · It is important to note that clinical drug development failure due to poor drug-like properties has been significantly improved in the past 20 years 29, which suggests the right strategy in drug-like property optimization. However, overall success rate of clinical drug development has not been significantly improved and remained at low of 10% ...
People also ask
What is affinity in pharmacology?
What is drug-target affinity (DTA)?
What is a drug-target binding affinity graph?
Can machine learning predict drug-target affinity?
Oct 21, 2020 · Affinity selection-mass spectrometry (AS-MS) is a high-throughput screening (HTS) technique for drug discovery that enables rapid screening of large collections of compounds to identify ligands ...
- Renaud Prudent, D. Allen Annis, Peter J. Dandliker, Jean-Yves Ortholand, Didier Roche
- 2021
Jan 1, 2023 · This process takes an average of 10–15 years. After accounting for the costs of failed trials, the median capitalized research and development investment to bring a new drug to market has been estimated at $985.3 million (95% CI, $683.6–$1228.9 million), and the mean investment was estimated at $1335.9 million (95% CI, $1042.5–$1637.5 ...
Apr 1, 2024 · 1 Introduction. Drug-target affinity (DTA) is a critical metric and the core of drug discovery. While the wet experiments have been used to calculate DTA with high accuracy, the time-consuming and laborious nature of these experiments can no longer meet the demands of modern drug screening, especially with the massive drug-target pairs.
Feb 16, 2024 · Background High-performance computing plays a pivotal role in computer-aided drug design, a field that holds significant promise in pharmaceutical research. The prediction of drug–target affinity (DTA) is a crucial stage in this process, potentially accelerating drug development through rapid and extensive preliminary compound screening, while also minimizing resource utilization and costs ...
Aug 6, 2018 · The old concepts of affinity to define drug selectivity and intrinsic efficacy to define drug action that have been guiding principles for drug development for over 50 years are no longer tenable. It is important to consider that most, if not all, receptors have constitutive activity and most, if not all, antagonist drugs have inverse agonist ...
